Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Randomized, Double-blind, Placebo-controlled Trial of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses of GSBR-1290 in Japanese and Non-Japanese Healthy Volunteers

NCT05893043 is registered in ClinicalTrials.gov with Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics as lead sponsor.

NCT NCT05893043
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05893043 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Randomized, Double-blind, Placebo-controlled Trial of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses of GSBR-1290 in Japanese and Non-Japanese Healthy Volunteers
Lead sponsor
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
April 24, 2023
Completion date
June 28, 2023
Enrollment
18 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteers